Shanghai institutions launch breast cancer biomarker study using 10x Genomics' Xenium

10x Genomics said on November 10, 2026 that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx) will deploy its Xenium platform in a 24-month study. 10x Genomics said the study aims to identify biomarkers that may predict how patients with breast cancer respond to neoadjuvant therapy, which is treatment given before surgery to shrink tumors.

10x Genomics said researchers will use the Xenium platform to profile tumor gene expression in each tumor and compare those findings with treatment outcomes, to identify cellular features and pathways linked to treatment response and resistance. The company said the study has the potential for future expansion to its Atera platform.

10x Genomics said FUSCC and SPDx intend to use the study's findings to inform their development of potential future diagnostic approaches. Zhimin Shao, Director of the Breast Cancer Center at FUSCC, said patients with breast cancer can respond very differently to the same treatment, and that reliable tools to predict those differences are still lacking. Tong Zhou, CEO of SPDx, said the collaboration combines FUSCC's clinical expertise with the cellular-resolution view of tumors provided by Xenium.

In 2026, 10x Genomics outlined two paths for single cell and spatial technologies in diagnostics. The company said the study follows the path in which customers use 10x technologies in translational research, and that it complements oncology academic collaborations 10x Genomics announced earlier in the year. 10x Genomics said Roman Yelensky, Vice President, Clinical Applications at 10x Genomics, said FUSCC and SPDx are pursuing research needed to make that future possible.